Lista de obras - Nancy Sullivan - Dominio Público Uruguay

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

artículo científico publicado en 2006

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

artículo científico publicado en 2016

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

artículo científico publicado en 2015

A new approach for monitoring ebolavirus in wild great apes

artículo científico publicado en 2014

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

artículo científico publicado en 2020

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

artículo científico publicado en 2010

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

artículo científico publicado en 2003

Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors

artículo científico publicado en 2014

Antibodies and resistance to natural HIV infection

artículo científico publicado en 2000

Antibody-mediated enhancement of viral disease.

artículo científico publicado en 2001

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

artículo científico publicado en 2010

CCR5 Has an Expanded Ligand-Binding Repertoire and Is the Primary Receptor Used by MCP-2 on Activated T Cells ⬇️

artículo científico publicado el 1 de noviembre de 1998

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

artículo científico publicado en 1997

CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization ⬇️

artículo científico publicado el 1 de junio de 1998

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

artículo científico publicado en 2011

CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus

scientific article published on 17 July 2019

Camouflage and misdirection: the full-on assault of ebola virus disease

artículo científico publicado en 2014

Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120

scientific journal article

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

artículo científico publicado en 2014

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report

artículo científico publicado en 2015

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

artículo científico publicado en 2014

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

scientific article published on May 2009

Defining the risk of SARS-CoV-2 variants on immune protection

artículo científico publicado en 2022

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

artículo científico publicado en 2010

Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor.

artículo científico publicado en 2006

Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies ⬇️

artículo científico publicado el 1 de agosto de 1998

Development of a preventive vaccine for Ebola virus infection in primates

artículo científico publicado en 2000

Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques

artículo científico publicado en 2015

Ebola Immunity: Gaining a Winning Position in Lightning Chess

Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway

artículo científico publicado en 2005

Ebola virus pathogenesis: implications for vaccines and therapies

artículo científico publicado en 2003

Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway ⬇️

artículo científico publicado el 12 de enero de 2011

Ebolavirus vaccines for humans and apes ⬇️

artículo científico publicado el 4 de mayo de 2012

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.

artículo científico publicado en 1993

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic

artículo científico publicado en 2017

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection

scientific journal article

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

artículo científico publicado en 2020

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names

artículo científico publicado en 2014

Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences

artículo científico publicado en 2012

Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

artículo científico publicado en 1993

Functional interrogation and mining of natively paired human VH:VL antibody repertoires

artículo científico publicado en 2018

High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19

artículo científico publicado en 2021

Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding

artículo científico publicado en 1996

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

artículo científico publicado en 1996

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury

artículo científico publicado en 2000

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

artículo científico publicado en 2021

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

artículo científico publicado en 2006

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

artículo científico

Immunopathology of highly virulent pathogens: insights from Ebola virus

artículo científico publicado en 2007

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant

artículo científico publicado en 2012

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

artículo científico publicado en 2005

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

artículo científico publicado en 2007

Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.

artículo científico publicado en 1995

Overexpression of Ebola virus envelope GP1 protein

artículo científico publicado en 2017

Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains

artículo científico publicado en 1993

Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

artículo científico publicado en 2016

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

artículo científico publicado en 2011

Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein ⬇️

artículo científico publicado el 1 de diciembre de 1997

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

artículo científico publicado en 1995

Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial

artículo científico publicado en 2014

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

artículo científico publicado en 2014

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

artículo científico publicado en 2015

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo

artículo científico publicado en 2018

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

artículo científico publicado en 2021

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

artículo científico publicado en 2016

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

artículo científico publicado en 2020

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

artículo científico publicado en 2020

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes ⬇️

artículo científico publicado en 2020

Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus ⬇️

artículo científico publicado el 1 de abril de 1992

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

artículo científico publicado en 1996

Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection ⬇️

artículo científico publicado el 4 de agosto de 1997

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

artículo científico publicado en 2015

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

artículo científico publicado en 2021

Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures

artículo científico publicado en 2018

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

artículo científico publicado en 2017

Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction

scholarly article by Alberto Cagigi et al published 22 November 2018 in Journal of Infectious Diseases

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

artículo científico publicado en 2010

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA

artículo científico publicado en 2013

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae

artículo científico publicado en 2013

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

scholarly article by Kizzmekia Corbett et al published 20 August 2021 in Nature Immunology

Lista de obras de Nancy Sullivan

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

A new approach for monitoring ebolavirus in wild great apes

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors

Antibodies and resistance to natural HIV infection

Antibody-mediated enhancement of viral disease.

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

CCR5 Has an Expanded Ligand-Binding Repertoire and Is the Primary Receptor Used by MCP-2 on Activated T Cells ⬇️

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization ⬇️

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

CD8β Depletion Does Not Prevent Control of Viral Replication or Protection from Challenge in Macaques Chronically Infected with a Live Attenuated Simian Immunodeficiency Virus

Camouflage and misdirection: the full-on assault of ebola virus disease

Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

Defining the risk of SARS-CoV-2 variants on immune protection

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor.

Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies ⬇️

Development of a preventive vaccine for Ebola virus infection in primates

Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques

Ebola Immunity: Gaining a Winning Position in Lightning Chess

Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway

Ebola virus pathogenesis: implications for vaccines and therapies

Ebolavirus Proteins Suppress the Effects of Small Interfering RNA by Direct Interaction with the Mammalian RNA Interference Pathway ⬇️

Ebolavirus vaccines for humans and apes ⬇️

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic

Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names

Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences

Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

Functional interrogation and mining of natively paired human VH:VL antibody repertoires

High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19

Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

Immunopathology of highly virulent pathogens: insights from Ebola virus

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.

Overexpression of Ebola virus envelope GP1 protein

Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains

Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein ⬇️

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes ⬇️

Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus ⬇️

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

Two Orphan Seven-Transmembrane Segment Receptors Which Are Expressed in CD4-positive Cells Support Simian Immunodeficiency Virus Infection ⬇️

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates